A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura® (clinicaltrials.gov) - Sep 25, 2026 - P=N/A | N=670 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed • Real-world evidence • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|